ISBN: 978-1-4731-3093-7 Study Intervention and comparison Population Outcomes Comments maximally tolerated medical management and target doses of a renin-angiotensin system inhibitor, a beta-adrenoceptor antagonist and an aldosterone antagonist Gender (M/F): Ethnicity not reported UK Domiciliary oxygen therapy in people with advanced heart failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Table 144: Clinical evidence summary: long term oxygen therapy versus best medical therapy Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Best medical therapy Risk difference with Long term oxygen therapy (95% CI) Quality of life (MLWHF) VERY LOWa,b,c due to risk of bias, indirectness, imprecision The mean quality of life (MLWHF) in the control groups was The mean quality of life (MLWHF) in the intervention groups was Quality of life (EQ- VERY LOWa,b due to risk of bias, indirectness The mean quality of life (EQ-5D-3L) in the control groups was The mean quality of life (EQ-5D-3L) in the intervention groups was (0.1 lower to 0.12 higher) VERY LOWa,b,c due to risk of bias, indirectness, imprecision Rate ratio 360 events per 1000 person-years 54 fewer events per 1000 person-years (from 165 fewer to 119 more) NRS for breathlessness (Scale from: 0 to 10) VERY LOWa,b,c due to risk of bias, indirectness, imprecision d The mean NRS for breathlessness in the intervention group was (1.57 lower to 0.31 higher) 6 minute walk test 74 VERY LOWa,b due to risk of bias, indirectness d The mean 6 minute walk test in the intervention group was 0.64 metres higher (34.54 lower to 35.82 higher) (a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias. 